. Curr Rheumatol Rep 2014;16:412.
High prevalence of BRAF V600E mutations in Erdheim-Chester disease
but not in other non-Langerhans cell histiocytoses.
has numerous signs and symptoms.
- The US Food and Drug Administration has approved Zelboraf (vemurafenib) for Erdheim-Chester disease
with BRAF V600 mutation.
Swiss healthcare company Hoffman-LaRoche Inc reported on Monday the receipt of expanded approval from the US Food and Drug Administration for Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease
(ECD) of the blood.
. Clinical and radiologic characteristics of 59 cases.
Parisi, "Neurological manifestations of Erdheim-Chester disease
," Journal of Neurology, Neurosurgery, and Psychiatry, vol.
Caparros-Lefebvre et al., "Erdheim-Chester disease
. Clinical and radiologic characteristics of 59 cases," Medicine, vol.
of the breast: a case report and review of the literature.
Annes et al., "Erdheim-Chester disease
presenting with cutaneous involvement: a case report and literature review," Journal of Cutaneous Pathology, vol.
is a systemic histiocytic disorder diagnosed on the basis of a characteristic pattern of symmetric intramedullary sclerosis of long bones.
And how do people living with rare illnesses such as Erdheim-Chester disease
cope when treatment, research and services are limited?